US-based GE Healthcare announced this week that Taiwan’s United BioPharma Inc. (UBP) had selected GE Healthcare’s FlexFactory manufacturing platform for its new facility in Hsinchu, Taiwan, focusing on late-stage clinical and commercial production capacity of therapeutic monoclonal antibodies.Read more
Taiwan’s biotech and pharmaceutical industry was one of the first to be named in the original Tsai Administration’s 5+2 economic policy to transform the nation’s economic structure, and is viewed as the upcoming medical treatment trend that Taiwan cannot miss out on, said Johnsee Lee, the Honorary Chairman of Taiwan Bio Industry Organization (Taiwan BIO) during the Precision Medicine Industry Forum 2017 in Taipei, Wednesday.Read more
Chipscreen Biosciences Ltd. executives She Liang-ji, VP, Oncology Division, and Xin Fu, Medical Affairs Manager (left) meeting with GNTbm's President Alex Chen (right) in Taipei, Taiwan, in February this year.
GNT Biotech & Medicals Co., Ltd., (GNTbm) (TPEx: 7427) has announced that the anticancer drug Chidamide (HBI-8000), an epigenetic regulator developed by Chipscreen Biosciences Ltd., of Shenzhen, China, had received approval from the Taiwan Food and Drug Administration (TFDA) to begin a Phase III clinical trial in Taiwan for hormone receptor-positive, HER-2 negative late stage breast cancer.Read more
A delegation from the Pharmaceutical Research and Manufacturers of America (PhRMA) made a recent visit to Taiwan and while here urged the government to pass laws that would better strengthen intellectual property protection for pharmaceuticals.Read more
Tainan-headquartered ScinoPharm Taiwan (1789, TaiEx), the country’s leading API manufacturer, will continue its strategy of producing high barrier-to-entry API while vertically expanding its offering to encompass the manufacturing of finished injectable products, reported Chen Yung-fa, ScinoPharm’s President & CEO in a recent interview with PharmaBoardroom.Read more
Taipei, Taiwan-headquartered TaiGen Biotechnology Co., Ltd. announced today that its wholly owned Chinese subsidiary, TaiGen Biopharmaceuticals Co. (Beijing), Ltd. has executed an equity purchase agreement to sell its 9% equity stake in Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd., a joint venture company between TGBJ and HEC, to Chinese pharma company YiChang HEC ChangJiang Pharmaceutical Co., Ltd.Read more